FDA全球物质注册数据库(FDA Global Substance Registration System)
物质名称IZURALIMAB
异名/同义词IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS ICOS (INDUCIBLE T-CELL COSTIMULATORY, ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE, AILIM, CD278)) AND ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
IMMUNOGLOBULIN, ANTI-(HUMAN PROGRAMMED CELL DEATH 1) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB23104 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260->234'),(263->237')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1-ANTI-(HUMAN INDUCIBLE COSTIMULATOR) (HUMAN MONOCLONAL XMAB23104 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL XMAB23104 .KAPPA.-CHAIN
IZURALIMAB
IZURALIMAB [INN]
IZURALIMAB [USAN]
IZURALIMAB [WHO-DD]
XMAB23104
XMAB-23104
CAS登记号2329669-80-7
物质唯一标识(Unique Ingredient Identifier)9D2R4T39AY
分子式
国际化合物标识(International Chemical Identifier,InChI)
SMILES
分子结构式
欧洲化学品管理局注册号(ECHA)
成分类型 / INGREDIENT SUBSTANCE
关联数据
  • 药品国际非专利名称数据库
  • 世界卫生组织药物词典
扩展资源
©2006-2026 Drugfuture->FDA Global Substance Registration System